Evidence-Based Guideline for the management of osteoporosis in men
Nicholas R. Fuggle,Charlotte Beaudart,Olivier Bruyère,Bo Abrahamsen,Nasser Al-Daghri,Nansa Burlet,Manju Chandran,Mario M. Rosa,Bernard Cortet,Céline Demonceau,Willard Dere,Philippe Halbout,Mickaël Hiligsmann,John A. Kanis,Jean-Marc Kaufman,Andreas Kurth,Olivier Lamy,Andrea Laslop,Stefania Maggi,Radmila Matijevic,Eugene McCloskey,Ali Mobasheri,Maria C. Prieto Yerro,Régis P. Radermecker,Shaun Sabico,Yousef Al-Saleh,Stuart Silverman,Nicola Veronese,René Rizzoli,Cyrus Cooper,Jean-Yves Reginster,Nicholas C. Harvey
DOI: https://doi.org/10.1038/s41584-024-01094-9
IF: 32.286
2024-03-15
Nature Reviews Rheumatology
Abstract:Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
rheumatology